Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
2 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
5 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
6 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
7 Chemokine signaling pathway 💬
2件: JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
8 Chemokine signaling pathway 💬
2件: JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
9 Cholinergic synapse 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
10 Cholinergic synapse 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
11 Coronavirus disease - COVID-19 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
12 Coronavirus disease - COVID-19 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
13 Efferocytosis 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
14 Efferocytosis 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
15 Epstein-Barr virus infection 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
16 Epstein-Barr virus infection 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
17 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
18 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
19 Hepatitis B 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
20 Hepatitis B 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
21 Hepatitis C 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
22 Hepatitis C 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
23 Herpes simplex virus 1 infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
24 Herpes simplex virus 1 infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
25 Hormone signaling 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
26 Hormone signaling 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
27 Human cytomegalovirus infection 💬
1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
28 Human cytomegalovirus infection 💬
1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
29 Human papillomavirus infection 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
30 Human papillomavirus infection 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
31 Human T-cell leukemia virus 1 infection 💬
2件: JAK1, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
32 Human T-cell leukemia virus 1 infection 💬
2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
33 Influenza A 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
34 Influenza A 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
35 JAK-STAT signaling pathway 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
36 JAK-STAT signaling pathway 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
37 Kaposi sarcoma-associated herpesvirus infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
38 Kaposi sarcoma-associated herpesvirus infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
39 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
40 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
41 Lipid and atherosclerosis 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
42 Lipid and atherosclerosis 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
43 Measles 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
44 Measles 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
45 Necroptosis 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
46 Necroptosis 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
47 NOD-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
48 NOD-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
49 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
50 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
51 Osteoclast differentiation 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
52 Osteoclast differentiation 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
53 Pancreatic cancer 💬
1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
54 Pancreatic cancer 💬
1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
55 Pathways in cancer 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
56 Pathways in cancer 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
57 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
58 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
59 PI3K-Akt signaling pathway 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
60 PI3K-Akt signaling pathway 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
61 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
62 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
63 Prolactin signaling pathway 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
64 Prolactin signaling pathway 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
65 Signaling pathways regulating pluripotency of stem cells 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
66 Signaling pathways regulating pluripotency of stem cells 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
67 Th1 and Th2 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
68 Th1 and Th2 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
69 Th17 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
70 Th17 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
71 Toll-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
72 Toll-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
73 Toxoplasmosis 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
74 Toxoplasmosis 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
75 Tuberculosis 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
76 Tuberculosis 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
77 Viral carcinogenesis 💬
2件: JAK1, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
78 Viral carcinogenesis 💬
2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬